#ES­MO22: Da­ta on two key check­point fail­ures high­light Mer­ck­'s dom­i­nance in ad­ju­vant set­ting

PARIS — Mer­ck came in­to ES­MO con­fi­dent that it reigned supreme in the ad­ju­vant set­ting for re­nal cell car­ci­no­ma — the new fron­tier for check­point in­hibitors. It will leave feel­ing even bet­ter.

Just days af­ter spelling out the lat­est, im­proved haz­ard ra­tio for King Keytru­da — cut­ting risks for kid­ney can­cer pa­tients on dis­ease free sur­vival by 32% re­port­ed on ap­proval and jump­ing to 37% in the lat­est up­date in KEYNOTE-564 — we can see just how bad­ly Roche’s PD-L1 Tecen­triq per­formed in IM­mo­tion010, with an HR of 0.93.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER